Get the latest news, insights, and market updates on NTRA (Natera, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Natera Submits Signatera™ CDx PMA to FDA
AUSTIN, Texas, February 02, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signatera™ CDx for detection of molecular residual disease (MRD) in patients with muscle-invasive bladder cancer (MIBC) who may benefit from treatment with atezolizumab (Tecentriq®). Feb 2, 2026 - $NTRA
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
AUSTIN, Texas, January 28, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera’s Prospera Heart test can replace routine invasive biopsies for rejection monitoring in heart transplant recipients. Jan 28, 2026 - $NTRA
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
AUSTIN, Texas, January 26, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplantation Direct. The study, which was conducted by The Ohio State University Wexner Medical Center (OSU-WMC), was initiated to explore whether donor-derived cell-free DNA (dd-cfDNA) surveillance, and specifically Prospera-guided monitoring, could reduce the number of invasive biopsies for patients foll Jan 26, 2026 - $NTRA
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning. Jan 26, 2026 - $NTRA
Is It Too Late To Consider Natera (NTRA) After A 4x Three Year Share Price Surge
If you are wondering whether Natera's share price still lines up with its fundamentals, you are not alone. This article focuses squarely on what the current valuation might mean for you. Natera's stock last closed at US$241.58, with returns of 4.5% over 7 days, 2.6% over 30 days, 5.6% year to date, 44.1% over 1 year and a very large gain of around 4.5x over 3 years, as well as 126.5% over 5 years. Recent market interest in Natera has been shaped by ongoing attention on the wider genetic... Jan 24, 2026 - $NTRA
Lack of Natera (NTRA) Exposure Weighs on Voya MidCap Opportunities Fund Performance
Voya Investment Management’s Voya MidCap Opportunities Fund released its Q4 2025 investor letter, titled “Seeking a More Favorable Risk/Return Trade-off”, outlining a quarter marked by solid market gains but relative fund underperformance. A copy of the letter can be downloaded here. During the quarter, the Fund underperformed its benchmark, the Russell Mid Cap Growth Index, […] Jan 23, 2026 - $NTRA
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
AUSTIN, Texas, January 21, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free molecular residual disease assay (tfMRD) in colorectal cancer (CRC). The peer-reviewed publication builds upon data that was previously presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). Jan 21, 2026 - $NTRA
Natera (NTRA) Surged as Results Beat Expectations
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ended the fourth quarter on a strong note, with the S&P surging 2.7%, maintaining its steady upward momentum. Investors’ optimism was supported by better-than-expected corporate […] Jan 20, 2026 - $NTRA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple